Neurocrine Biosciences
NBIX
#1375
Rank
$15.37 B
Marketcap
$154.22
Share price
1.49%
Change (1 day)
20.73%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2025 : $0.42 Billion USD

According to Neurocrine Biosciences 's latest financial reports the company's total debt is $0.42 Billion USD. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31$0.45 B6.23%
2023-12-31$0.42 B62.95%
2022-12-31$0.26 B-40.3%
2021-12-31$0.44 B6.82%
2020-12-31$0.41 B-16.79%
2019-12-31$0.49 B27.54%
2018-12-31$0.38 B5.11%
2017-12-31$0.36 B
2009-12-31$11.53 M-25.12%
2008-12-31$15.39 M936.14%
2007-12-31$1.48 M-97.23%
2006-12-31$53.64 M-9.7%
2005-12-31$59.4 M-10.17%
2004-12-31$66.12 M81.5%
2003-12-31$36.43 M359.14%
2002-12-31$7.93 M39.53%
2001-12-31$5.68 M46.95%
2000-12-31$3.87 M24.84%
1999-12-31$3.1 M3.33%
1998-12-31$3 M87.5%
1997-12-31$1.6 M0%
1996-12-31$1.6 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Repligen
RGEN
$0.68 B 60.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
$8.94 B 1,988.17%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
$0.26 M-99.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
$42.50 B 9,822.18%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
$68.74 B 15,946.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
$60.84 B 14,103.55%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
$0.62 B 44.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
$18.57 M-95.66%๐Ÿ‡บ๐Ÿ‡ธ USA